Adjuvant Capital
Edit

Adjuvant Capital

https://adjuvantcapital.com
Last activity: 09.02.2024
Invests in categories: HealthTechTechnologyBioTechDevelopmentResearchProductMedtechPlatformDrugIT
Adjuvant is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public health challenges.
Portfolio
20
Persons
4
Mentions
33
Employees: 11-50
Investment Stage: Series A; Series B; Series E

Portfolio 20

DateNameWebsiteTotal RaisedLocation
22.11.2023YS Biophar...ysbiopharm...-China, Bei...
08.11.2023LimmaTech ...lmtbio.com$39.5MSwitzerlan...
27.04.2023Antiva Bio...antivabio....$137MUnited Sta...
15.02.2023Codagenixcodagenix....$47MUnited Sta...
03.02.2021Frontier N...frontiernu...$6MUnited Sta...
15.04.202054gene54gene.com$64.5MUnited Sta...
-Excision B...excision.b...-United Sta...
-Pulmocidepulmocide....$174MUnited Kin...
-Memo Thera...memo-thera...$84.15MSwitzerlan...
-Yisheng Bi...yishengbio...-China, Bei...
Show more

Persons 4

DateFirst NameLast NameTitleLinkedInLocation
-GiuliaBalconi-linkedin.c...-
-AbrarHaque-linkedin.c...-
-CharliePetty-linkedin.c...-
-Alexandra(Sandra) G...-linkedin.c...-

Mentions in press and media 33

DateTitleDescriptionSource
02.02.2024New investment brings LimmaTech’s series A to CHF 40 million... Emerging antimicrobial resistance worldwide presents a serious public health threat. Inappropriate ...startuptic...
02.11.2023Memo Therapeutics Raises CHF 25 Million Series C Financingstartuptic...
10.10.2023Swiss-based LimmaTech Biologics raises €35M to combat emergi...Read this article in: Zurich-based LimmaTech Biologics AG, a clinical-stage biopharmaceutical compan...siliconcan...
09.10.2023First equity funding for LimmaTech Biologicsstartuptic...
16.02.2022Memo Therapeutics raises CHF 23 millionstartuptic...
16.09.202154gene Closes $25M Series B to Advance Global Drug Discovery...prnewswire...
07.07.2021VitriVax Announces Series A Financing to Further Demonstrate...prnewswire...
27.05.2021IP : Pulmocide Ltd - Raises $92 million in a Series C financ...Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled ther...marketscre...
27.05.2021IP GROUP PLC IP : Pulmocide Ltd - Raises $92 million in a S...Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled ther...marketscre...
04.05.2021US life science investment firm establishes European presenc...startuptic...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In